NO326996B1 - Anvendelse av trombininhibitor for fremstilling av et medikament for dialysebehandling. - Google Patents

Anvendelse av trombininhibitor for fremstilling av et medikament for dialysebehandling. Download PDF

Info

Publication number: NO326996B1
Authority: NO; Norway
Prior art keywords: dialysis; melagatran; molecular weight; low molecular; thrombin inhibitor
Prior art date: 1999-01-11

Application number

NO20013301A

Other languages

English (en)

Norwegian (no)

Other versions

NO20013301D0 (no

NO20013301L (no

Inventor

Gunnar Fager

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-11

Filing date

2001-07-03

Publication date

2009-03-30

2001-07-03 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2001-07-03 Publication of NO20013301D0 publication Critical patent/NO20013301D0/no

2001-07-03 Publication of NO20013301L publication Critical patent/NO20013301L/no

2009-03-30 Publication of NO326996B1 publication Critical patent/NO326996B1/no

Links

238000000502 dialysis Methods 0.000 title claims abstract description 90
229940122388 Thrombin inhibitor Drugs 0.000 title claims abstract description 50
239000003868 thrombin inhibitor Substances 0.000 title claims abstract description 50
101000712605 Theromyzon tessulatum Theromin Proteins 0.000 title claims abstract description 27
238000011282 treatment Methods 0.000 title claims abstract description 20
239000003814 drug Substances 0.000 title claims abstract description 9
238000002360 preparation method Methods 0.000 title description 2
229960002137 melagatran Drugs 0.000 claims abstract description 48
DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 claims abstract description 48
239000000385 dialysis solution Substances 0.000 claims abstract description 33
238000001631 haemodialysis Methods 0.000 claims abstract description 17
230000000322 hemodialysis Effects 0.000 claims abstract description 16
238000004519 manufacturing process Methods 0.000 claims abstract description 3
229940002612 prodrug Drugs 0.000 claims description 10
239000000651 prodrug Substances 0.000 claims description 10
229940079593 drug Drugs 0.000 claims description 7
108090000765 processed proteins & peptides Proteins 0.000 claims description 7
CDPROXZBMHOBTQ-SJORKVTESA-N 2-[[(2r)-3-cyclohexyl-1-[(2s)-2-[3-(diaminomethylideneamino)propylcarbamoyl]piperidin-1-yl]-1-oxopropan-2-yl]amino]acetic acid Chemical group NC(N)=NCCCNC(=O)[C@@H]1CCCCN1C(=O)[C@H](NCC(O)=O)CC1CCCCC1 CDPROXZBMHOBTQ-SJORKVTESA-N 0.000 claims description 3
150000001413 amino acids Chemical class 0.000 claims description 3
229950003291 inogatran Drugs 0.000 claims description 3
239000012141 concentrate Substances 0.000 abstract description 32
210000004369 blood Anatomy 0.000 description 31
239000008280 blood Substances 0.000 description 31
238000000034 method Methods 0.000 description 21
239000012528 membrane Substances 0.000 description 19
210000002381 plasma Anatomy 0.000 description 11
241000282887 Suidae Species 0.000 description 9
150000001875 compounds Chemical class 0.000 description 9
150000002500 ions Chemical class 0.000 description 9
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 8
239000003112 inhibitor Substances 0.000 description 8
NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 8
238000010790 dilution Methods 0.000 description 7
239000012895 dilution Substances 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
229960001025 iohexol Drugs 0.000 description 7
230000036470 plasma concentration Effects 0.000 description 7
239000000243 solution Substances 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
239000003146 anticoagulant agent Substances 0.000 description 6
230000006870 function Effects 0.000 description 6
229920000669 heparin Polymers 0.000 description 6
239000000203 mixture Substances 0.000 description 6
108090000190 Thrombin Proteins 0.000 description 5
238000001914 filtration Methods 0.000 description 5
229960002897 heparin Drugs 0.000 description 5
229960004072 thrombin Drugs 0.000 description 5
238000012384 transportation and delivery Methods 0.000 description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
229940127219 anticoagulant drug Drugs 0.000 description 4
230000015271 coagulation Effects 0.000 description 4
238000005345 coagulation Methods 0.000 description 4
238000009472 formulation Methods 0.000 description 4
239000008103 glucose Substances 0.000 description 4
238000005070 sampling Methods 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
208000001647 Renal Insufficiency Diseases 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000002429 anti-coagulating effect Effects 0.000 description 3
208000020832 chronic kidney disease Diseases 0.000 description 3
208000022831 chronic renal failure syndrome Diseases 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
201000006370 kidney failure Diseases 0.000 description 3
238000011321 prophylaxis Methods 0.000 description 3
238000004088 simulation Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000001732 thrombotic effect Effects 0.000 description 3
IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
241001065350 Lundia Species 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
230000035602 clotting Effects 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
108010085662 ecarin Proteins 0.000 description 2
210000003191 femoral vein Anatomy 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000007789 gas Substances 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
230000002028 premature Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
XYGVIBXOJOOCFR-BTJKTKAUSA-N (z)-but-2-enedioic acid;8-chloro-6-(2-fluorophenyl)-1-methyl-4h-imidazo[1,5-a][1,4]benzodiazepine Chemical compound OC(=O)\C=C/C(O)=O.C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F XYGVIBXOJOOCFR-BTJKTKAUSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000009304 Acute Kidney Injury Diseases 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
201000003126 Anuria Diseases 0.000 description 1
206010003226 Arteriovenous fistula Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
244000025254 Cannabis sativa Species 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
206010014418 Electrolyte imbalance Diseases 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
206010016717 Fistula Diseases 0.000 description 1
206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
208000033626 Renal failure acute Diseases 0.000 description 1
206010062237 Renal impairment Diseases 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
102000002262 Thromboplastin Human genes 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
201000011040 acute kidney failure Diseases 0.000 description 1
208000012998 acute renal failure Diseases 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000002785 anti-thrombosis Effects 0.000 description 1
230000010100 anticoagulation Effects 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
238000009811 bilateral tubal ligation Methods 0.000 description 1
238000004638 bioanalytical method Methods 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
229940072271 diprivan Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
230000003890 fistula Effects 0.000 description 1
239000013505 freshwater Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000000004 hemodynamic effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000035987 intoxication Effects 0.000 description 1
231100000566 intoxication Toxicity 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229960002725 isoflurane Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
229940127215 low-molecular weight heparin Drugs 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
238000003760 magnetic stirring Methods 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000008816 organ damage Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
-1 polyethylene Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
231100000857 poor renal function Toxicity 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
238000005086 pumping Methods 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
210000002254 renal artery Anatomy 0.000 description 1
210000002796 renal vein Anatomy 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000002537 thrombolytic effect Effects 0.000 description 1
238000004448 titration Methods 0.000 description 1
239000002699 waste material Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1654—Dialysates therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/342—Adding solutions to the blood, e.g. substitution solutions
- A61M1/3424—Substitution fluid path
- A61M1/3427—Substitution fluid path back through the membrane, e.g. by inverted trans-membrane pressure [TMP]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3672—Means preventing coagulation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Heart & Thoracic Surgery (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Anesthesiology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Diabetes (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
External Artificial Organs (AREA)
Separation Using Semi-Permeable Membranes (AREA)
Peptides Or Proteins (AREA)

NO20013301A 1999-01-11 2001-07-03 Anvendelse av trombininhibitor for fremstilling av et medikament for dialysebehandling. NO326996B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9900043A SE9900043D0 (sv)	1999-01-11	1999-01-11	New use
PCT/SE2000/000030 WO2000041715A1 (en)	1999-01-11	2000-01-11	New dialysis method

Publications (3)

Publication Number	Publication Date
NO20013301D0 NO20013301D0 (no)	2001-07-03
NO20013301L NO20013301L (no)	2001-07-03
NO326996B1 true NO326996B1 (no)	2009-03-30

Family

ID=20414050

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20013301A NO326996B1 (no)	1999-01-11	2001-07-03	Anvendelse av trombininhibitor for fremstilling av et medikament for dialysebehandling.

Country Status (19)

Country	Link
US (4)	US20030042202A1 (zh)
EP (1)	EP1144000B1 (zh)
JP (1)	JP4054533B2 (zh)
KR (1)	KR100840452B1 (zh)
CN (1)	CN100387296C (zh)
AT (1)	ATE316384T1 (zh)
AU (1)	AU763185B2 (zh)
BR (1)	BR0007448A (zh)
CA (1)	CA2356440A1 (zh)
CY (1)	CY1107461T1 (zh)
DE (1)	DE60025698T2 (zh)
DK (1)	DK1144000T3 (zh)
ES (1)	ES2255968T3 (zh)
IL (1)	IL143824A0 (zh)
NO (1)	NO326996B1 (zh)
NZ (1)	NZ512712A (zh)
SE (1)	SE9900043D0 (zh)
WO (1)	WO2000041715A1 (zh)
ZA (1)	ZA200105274B (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1466916B1 (en)	2002-09-09	2007-10-24	Trigen Limited	Peptide boronic acids useful in making salts thereof
US7112572B2 (en)	2002-09-09	2006-09-26	Trigen Limited	Multivalent metal salts of boronic acids
US7235589B2 (en) *	2004-09-21	2007-06-26	Bio Numerik Pharmaceuticals, Inc.	Method of treating patients undergoing kidney dialysis
CN105115949B (zh) *	2005-12-21	2018-06-22	梅索斯卡莱科技公司	分析装置、方法和试剂
CA3122671A1 (en)	2005-12-21	2008-05-15	Meso Scale Technologies, Llc.	Assay apparatuses, methods and reagents
US20070155672A1 (en) *	2006-01-05	2007-07-05	Markus Voges	Sterilized peritoneal dialysis solutions containing heparin
ES2647775T3 (es) *	2011-08-02	2017-12-26	Medtronic, Inc.	Sistema de hemodiálisis que tiene una trayectoria de flujo con un volumen distensible controlado
US9623164B2 (en)	2013-02-01	2017-04-18	Medtronic, Inc.	Systems and methods for multifunctional volumetric fluid control
US10010663B2 (en)	2013-02-01	2018-07-03	Medtronic, Inc.	Fluid circuit for delivery of renal replacement therapies
US10850016B2 (en)	2013-02-01	2020-12-01	Medtronic, Inc.	Modular fluid therapy system having jumpered flow paths and systems and methods for cleaning and disinfection
US10874787B2 (en)	2014-12-10	2020-12-29	Medtronic, Inc.	Degassing system for dialysis
US9713665B2 (en)	2014-12-10	2017-07-25	Medtronic, Inc.	Degassing system for dialysis
US10098993B2 (en)	2014-12-10	2018-10-16	Medtronic, Inc.	Sensing and storage system for fluid balance
US11278654B2 (en)	2017-12-07	2022-03-22	Medtronic, Inc.	Pneumatic manifold for a dialysis system
US11033667B2 (en)	2018-02-02	2021-06-15	Medtronic, Inc.	Sorbent manifold for a dialysis system
US11110215B2 (en)	2018-02-23	2021-09-07	Medtronic, Inc.	Degasser and vent manifolds for dialysis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU178398B (en) *	1979-06-12	1982-04-28	Gyogyszerkutato Intezet	Process for producing new agmatine derivatives of activity against haemagglutination
US4489535A (en) *	1980-10-02	1984-12-25	Veltman Preston Leonard	Materials and method for preparing dialysis solutions containing bicarbonate ions
GR870129B (en) *	1987-01-27	1987-02-04	Giatzidis Ippokratis	Stable bicarbonate - glycylglycine dialysate for hemodialysis and peritoneal dialysis
SE9103612D0 (sv) *	1991-12-04	1991-12-04	Astra Ab	New peptide derivatives
US5549674A (en) *	1992-03-02	1996-08-27	The Regents Of The University Of Michigan	Methods and compositions of a bioartificial kidney suitable for use in vivo or ex vivo
SE9301916D0 (sv) *	1993-06-03	1993-06-03	Ab Astra	New peptides derivatives
DE4321444A1 (de) *	1993-06-28	1995-01-05	Bernd Prof Dr Clement	Pharmazeutische Zubereitung
US5380299A (en) *	1993-08-30	1995-01-10	Med Institute, Inc.	Thrombolytic treated intravascular medical device
US5705487A (en) *	1994-03-04	1998-01-06	Eli Lilly And Company	Antithrombotic agents
US5707966A (en) *	1994-03-04	1998-01-13	Eli Lilly And Company	Antithrombotic agents
DE4443390A1 (de) *	1994-12-06	1996-06-13	Basf Ag	Neue dipeptidische p-Amidinobenzylamide mit N-terminalen Sulfonyl- bzw. Aminosulfonylresten
KR19980702112A (ko) *	1995-02-10	1998-07-15	페라 스타르크,요헨 카르크	트롬빈 억제제
US5710130A (en) *	1995-02-27	1998-01-20	Eli Lilly And Company	Antithrombotic agents
SE9600216D0 (sv) *	1996-01-18	1996-01-18	Hans Arne Hansson	Styrning av läkningsprocesser
CZ291690B6 (cs) *	1996-02-13	2003-05-14	Akzo Nobel N. V.	Inhibitory serinové proteázy a farmaceutický prostředek
EP0884325A1 (en) *	1997-04-24	1998-12-16	Akzo Nobel N.V.	Thrombin inhibitors containing a peptidyl heterocycle
CA2288224A1 (en) *	1997-04-30	1998-11-05	Mary George Johnson	Antithrombotic agents
AU7270798A (en) *	1997-05-01	1998-11-24	Eli Lilly And Company	Antithrombotic agents
WO1998050420A1 (en) *	1997-05-02	1998-11-12	Akzo Nobel N.V.	Serine protease inhibitors

1999
- 1999-01-11 SE SE9900043A patent/SE9900043D0/xx unknown
2000
- 2000-01-11 EP EP00901367A patent/EP1144000B1/en not_active Expired - Lifetime
- 2000-01-11 ES ES00901367T patent/ES2255968T3/es not_active Expired - Lifetime
- 2000-01-11 AU AU21409/00A patent/AU763185B2/en not_active Ceased
- 2000-01-11 KR KR1020017008703A patent/KR100840452B1/ko not_active IP Right Cessation
- 2000-01-11 DE DE60025698T patent/DE60025698T2/de not_active Expired - Lifetime
- 2000-01-11 JP JP2000593325A patent/JP4054533B2/ja not_active Expired - Fee Related
- 2000-01-11 BR BR0007448-9A patent/BR0007448A/pt not_active Application Discontinuation
- 2000-01-11 AT AT00901367T patent/ATE316384T1/de active
- 2000-01-11 NZ NZ512712A patent/NZ512712A/en not_active IP Right Cessation
- 2000-01-11 IL IL14382400A patent/IL143824A0/xx unknown
- 2000-01-11 CA CA002356440A patent/CA2356440A1/en not_active Abandoned
- 2000-01-11 CN CNB008026963A patent/CN100387296C/zh not_active Expired - Fee Related
- 2000-01-11 WO PCT/SE2000/000030 patent/WO2000041715A1/en active IP Right Grant
- 2000-01-11 DK DK00901367T patent/DK1144000T3/da active
2001
- 2001-06-26 ZA ZA200105274A patent/ZA200105274B/en unknown
- 2001-07-03 NO NO20013301A patent/NO326996B1/no not_active IP Right Cessation
2002
- 2002-03-18 US US10/098,625 patent/US20030042202A1/en not_active Abandoned
2005
- 2005-03-09 US US11/074,893 patent/US20050153904A1/en not_active Abandoned
2006
- 2006-04-19 CY CY20061100544T patent/CY1107461T1/el unknown
2007
- 2007-07-27 US US11/878,881 patent/US20080004225A1/en not_active Abandoned
2008
- 2008-08-12 US US12/222,604 patent/US20090192137A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20050153904A1 (en)	2005-07-14
EP1144000A1 (en)	2001-10-17
BR0007448A (pt)	2001-10-16
EP1144000B1 (en)	2006-01-25
CN1354673A (zh)	2002-06-19
AU2140900A (en)	2000-08-01
IL143824A0 (en)	2002-04-21
SE9900043D0 (sv)	1999-01-11
US20090192137A1 (en)	2009-07-30
KR100840452B1 (ko)	2008-06-20
US20030042202A1 (en)	2003-03-06
US20080004225A1 (en)	2008-01-03
JP2002534217A (ja)	2002-10-15
AU763185B2 (en)	2003-07-17
JP4054533B2 (ja)	2008-02-27
NZ512712A (en)	2004-09-24
ES2255968T3 (es)	2006-07-16
NO20013301D0 (no)	2001-07-03
NO20013301L (no)	2001-07-03
WO2000041715A1 (en)	2000-07-20
ATE316384T1 (de)	2006-02-15
CA2356440A1 (en)	2000-07-20
CY1107461T1 (el)	2012-12-19
DE60025698T2 (de)	2006-10-19
ZA200105274B (en)	2002-09-26
CN100387296C (zh)	2008-05-14
DE60025698D1 (de)	2006-04-13
KR20010093250A (ko)	2001-10-27
DK1144000T3 (da)	2006-05-08

Legal Events

Date	Code	Title	Description
2012-08-27	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US20080004225A1 (en)	2008-01-03	New dialysis method
US7351218B2 (en)	2008-04-01	Device and process for extracorporeal treatment by citrate anticoagulant
Henrich	2012	Principles and practice of dialysis
Stange et al.	1993	Dialysis against a recycled albumin solution enables the removal of albumin‐bound toxins
JP5275170B2 (ja)	2013-08-28	アクセス流を測定するための方法及び装置
US20130338560A1 (en)	2013-12-19	Method and apparatus for determining access flow
KR20050089833A (ko)	2005-09-08	이코덱스트린을 함유하는 생체친화성 투석액
JP2703582B2 (ja)	1998-01-26	透析装置
Shroff et al.	2022	Chronic hemodialysis in children
Mingardi et al.	1984	Heparin for hemodialysis: practical guidelines for administration and monitoring
Ashouri	1985	Regional sodium citrate anticoagulation in patients with active bleeding undergoing hemodialysis
Techert et al.	2007	High blood flow rates with adjustment of needle diameter do not increase hemolysis during hemodialysis treatment
Zhang et al.	2011	Clinical experience with nadroparin in patients undergoing dialysis for renal impairment
MXPA01007006A (es)	2002-03-05	Nuevo metodo de dialisis
Cheung	2009	Hemodialysis and hemofiltration
Cicchetti et al.	1993	Dialysis treatment using an ethylene vinyl alcohol membrane and no anticoagulation for chronic uremic patients
Hothi et al.	2016	Pediatric hemodialysis prescription, complications, and future directions
Sivalingam et al.	2007	Haemodialysis
Botan et al.	2023	Comparison of Citrate and Heparin for Continuous Renal Replacement Therapy in Pediatric Intensive Units
Munshi et al.	2016	Hemodialysis
JP2024085568A (ja)	2024-06-27	血液浄化装置
De Vos	2002	Anticoagulation therapy in acute renal failure extracorporeal treated patients
Rees	2009	73 Hemodialysis
Hayashi et al.	2002	Effects of activated factor X inhibitor, JTV-803, in a pig model of hemodialysis